PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL
First-line treatment with the integrase inhibitor dolutegravir (DTG) is associated with significant and progressive weight gain, especially among black women and if combined with TAF/FTC. If women become clinically obese after long-term treatment, this could increase risks of adverse birth and child health outcomes. This analysis assessed long-term risks of adverse outcomes in pregnancy and…